To date, the Akt inhibitor triciribine is the only drug shown to counteract the ZNF217-driven deleterious effects in vivo and has been proposed as a clinical strategy to treat ZNF217-positive cancer patients [10,119,162,163]. The gene discussed is AKT1; the disease is cancer.